- CEO
- Yong Jiang Xue
- Full Time Employees
- 1,501
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Changdu China
- IPO Date
- Sep 21, 2022
- Business
- Enwei Pharmaceutical Co., Ltd. is a China-based pharmaceutical enterprise engaged in the research, development, manufacturing, and commercialization of proprietary traditional Chinese medicines, chemical drugs, and personal healthcare products. The company develops and markets treatments across several core therapeutic categories through established brand lines, including Jieeryin, Haowayou, Likeshu, Zhongzhou, and Koubao. Its product portfolio comprises gynecological pharmaceuticals and feminine hygiene products, such as Jie'er Yin cleansing lotions, effervescent tablets, ointments, and miconazole nitrate vaginal soft capsules; pediatric and gastrointestinal medications, including Shanmai Jianpi oral liquid, Huaji oral liquid, and Jian'er pills; respiratory, cold, and pain relief treatments, including compound paracetamol and amantadine hydrochloride tablets, paracetamol and ibuprofen tablets, compound yinqiao aminomin capsules, antiviral oral liquid, and Jiawei Huoxiang Zhengqi mixture; and consumer health and intimate care products, including antimicrobial washes, skin care ointments, and oral hygiene solutions.
The company conducts its manufacturing activities through specialized subsidiaries, notably Sichuan Enwei Pharmaceutical Co., Ltd., operating modern production lines that cover multiple formulations such as lotions, ointments, oral liquids, tablets, granules, and capsules. Enwei Pharmaceutical markets and distributes its products throughout mainland China via retail pharmacy chains, hospitals, and rapidly growing third-party and direct-to-consumer e-commerce channels, employing a hybrid model of in-house marketing personnel and third-party distribution partners.
In recent strategic developments, Enwei Pharmaceutical significantly expanded its product portfolio through the restructuring and acquisition of Henan Xinxin Pharmaceutical Co., Ltd., securing 125 proprietary traditional Chinese medicine product approval licenses across respiratory, hepatobiliary, and tonifying therapeutic areas. Following this integration, the company initiated the commercial revival and outsourced manufacturing of priority acquired products, including antiviral oral liquid, qingre jiedu oral liquid, qinggan lidan oral liquid, and shengmai yin. Additionally, the company acquired the Marketing Authorization Holder rights for paracetamol and ibuprofen tablets to strengthen its respiratory and analgesic segment, scaled its dedicated pharmaceutical e-commerce operational division, and accelerated pipeline rollouts for traditional preparations including Wuji Baifeng pills.
Enwei Pharmaceutical Co., Ltd. was founded in 1986 and is headquartered in Chengdu, Sichuan Province, China.